Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itopride 200 mg in Heartburn
NCT00382577Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of itopride in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Forest Laboratories. Primary endpoint: 24-hour pH Monitoring at 5 days. Started Oct 2006; status: completed.
02
Drugs
itopride
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00382577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382577.